

12-22-00

A/REISSUE

12/20/00
jc867 U.S. PRO

Please type a plus sign (+) inside this box → ☒

PTO/SB/50 (4/98)
Approved for use through 09/30/2000 OMB 0651-0033
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REISSUE PATENT APPLICATION TRANSMITTAL

Address to:

**Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231**

Attorney Docket No.	CGD-002.0 US
First Named Inventor	Mark Pines
Original Patent Number	6,028,075
Original Patent Issue Date (Month/Day/Year)	2/22/00
Express Mail Label No.	EL378085135 US

APPLICATION FOR REISSUE OF:
(check applicable box)

☒ Utility Patent ☐ Design Patent ☐ Plant Patent

APPLICATION ELEMENTS

- ☒ * Fee Transmittal Form (PTO/SB/56)
(Submit an original, and a duplicate for fee processing)
- ☒ Specification and Claims (amended, if appropriate)
- ☐ Drawing(s) (proposed amendments, if appropriate)
- ☒ Reissue Oath / Declaration (original or copy)
(37 C.F.R. § 1.175)(PTO/SB/51 or 52)
- Original U.S. Patent
☒ Offer to Surrender Original Patent (37 C.F.R. § 1.178)
(PTO/SB/53 or PTO/SB/54)
or
☒ Ribboned Original Patent Grant
☐ Affidavit / Declaration of Loss (PTO/SB/55)
- Original U.S. Patent currently assigned?
☒ Yes ☐ No
(If Yes, check applicable box(es))
☒ Written Consent of all Assignees (PTO/SB/53 or 54)
☒ 37 C.F.R. § 3.73(b) Statement ☒ Power of Attorney

ACCOMPANYING APPLICATION PARTS

- ☐ Foreign Priority Claim (35 U.S.C. 119)
(if applicable)
- ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☐ English Translation of Reissue Oath/Declaration
(if applicable)
- ☐ * Small Entity Statement(s) ☒ Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- ☒ Other: Assignment
Request to Transfer Drawings
from Original Patent
Reissue Request & Amendments

*** NOTE FOR ITEMS 1 & 10: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).**

14. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label ☒ Correspondence address below
(Insert Customer No. or Attach bar code label here)


Name	Leon R. Yankwich				
Address	Yankwich & Associates 130 Bishop Allen Drive				
City	Cambridge	State	MA	Zip Code	02139
Country	USA	Telephone	(617) 491-4343	Fax	(617) 491-8801

NAME (Print/Type)	Leon R. Yankwich	Registration No. (Attorney/Agent)	30,237
Signature	<i>Leon R. Yankwich</i>	Date	12-19-2000

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

jc806 U.S. PRO
09/742993
12/20/00

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REISSUE APPLICATION FEE TRANSMITTAL FORM						Docket Number (Optional) CGD-002.0 US		
Claims as Filed - Part 1								
Claims in Patent	For	Number Filed in Reissue Application	(3) Number Extra	Small Entity		Other than a Small Entity		
				Rate	Fee	Rate	Fee	
(A) 3	Total Claims (37 CFR 1.16(j))	(B) 3	**** 0 =	x \$ 9 =	0	or	x \$ _____ =	
(C) 1	Independent Claims (37 CFR 1.16(i))	(D) 1	* 0 =	x \$ 40 =	0		x \$ _____ =	
Basic Fee (37 CFR 1.16(h))					\$355		\$ _____	
Total Filing Fee					\$355	OR	\$ _____	
Claims as Amended - Part 2								
	(1) Claims Remaining After Amendment		(2) Highest Number Previously Paid For	(3) Extra Claims Present	Small Entity		Other than a Small Entity	
					Rate	Fee	Rate	Fee
Total Claims (37 CFR 1.16(j))	*** 3	MINUS	** 9	* = 0	x \$ 9 =	0	or	x \$ _____ =
Independent Claims (37 CFR 1.16(i))	*** 1	MINUS	***** 1	= 0	x \$ 40 =	0		x \$ _____ =
Total Additional Fee					\$ 0	OR	\$ _____	
<p>* If the entry in (D) is less than the entry in (C), Write "0" in column 3.</p> <p>** If the "Highest Number of Total Claims Previously Paid For" is less than 20, Write "20" in this space.</p> <p>*** After any cancellation of claims</p> <p>**** If "A" is greater than 20, use (B - A); if "A" is 20 or less, use (B - 20).</p> <p>***** "Highest Number of Independent Claims Previously Paid For" or Number of Independent Claims in Patent (C).</p>								
<p><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____. A duplicate copy of this sheet is enclosed.</p> <p><input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required, or credit any overpayment to Deposit Account No. <u>50-0268</u>. A duplicate copy of this sheet is enclosed.</p> <p><input checked="" type="checkbox"/> A check in the amount of \$ <u>355.00 (#3325)</u> to cover the filing Additional fee is enclosed.</p>								
<u>12/19/2000</u> Date		 Signature of Applicant, Attorney or Agent of Record <u>LEON R. YANKWICH</u> Typed or printed name						

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Pines et al.
for Reissue of:	U.S. Pat. No. 6,028,075
Issued:	February 22, 2000
Based on Ser. No.:	08/797,703
Filed:	February 11, 1997
Entitled:	QUINAZOLINONE CONTAINING PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF NEOVASCULARIZATION AND FOR TREATING MALIGNANCIES

Attorney Docket No.: CGD-002.0 US

Assistant Commissioner for Patents
BOX REISSUE
Washington, D.C. 20231


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that the correspondence listed below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, in an envelope addressed to the Asst. Commissioner for Patents, BOX REISSUE, Washington, D.C. 20231 on the date indicated below.

1. Reissue Application Pursuant to 35 U.S.C. §251
2. Transmittal Form PTO/SB/50
3. Fee Transmittal Form PTO/SB/56
4. Request to Transfer Drawings from Original Patent
5. Establishment of Ownership & Consent of Assignees
6. Declaration by the Inventors
7. Offer to Surrender Patent
8. Assignment
9. Original U.S. Pat. No. 6,028,075
10. Cut-up copies of original patent
11. Check # 3325 in the amount of \$355.00
12. Return receipt postcard **EL378885135US**

Express Mailing Label No. = _____

date of deposit: December 20, 2000


Stephanie L. Pytlak
YANKWICH & ASSOCIATES
130 Bishop Allen Drive
Cambridge, MA 02139

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Reissue Application of: Pines et al.

for Reissue of: U.S. Pat. No. 6,028,075
Issued: February 22, 2000

Based on Ser. No.: 08/797,703
Filed: February 11, 1997

Entitled: QUINAZOLINONE CONTAINING
PHARMACEUTICAL COMPOSITIONS
FOR PREVENTION OF
NEOVASCULARIZATION AND FOR
TREATING MALIGNANCIES

Atty. Docket No.: CGD-002.0 US

Asst. Commissioner for Patents
BOX REISSUE
Washington, D.C. 20231


REQUEST TO TRANSFER DRAWINGS FROM ORIGINAL PATENT

Sir:

Pursuant to 37 C.F.R. §1.174, Applicants request that the drawings of the original patent, a copy of which is enclosed herewith, be transferred as formal drawings to the enclosed reissue application.

No alteration or correction has been made to these drawings.

Respectfully submitted,



Leon R. Yankwich, Reg. No. 30,237
David G. O'Brien, Reg. No. 46,125
Attorney's for Applicants
YANKWICH & ASSOCIATES
130 Bishop Allen Drive
Cambridge, MA 02139
telephone: (617) 491-4343
telecopier: (617) 491-8801

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Reissue Application of: Pines et al.

for Reissue of: U.S. Pat. No. 6,028,075
Issued: February 22, 2000

Based on Ser. No.: 08/797,703
Filed: February 11, 1997

Entitled: QUINAZOLINONE CONTAINING
PHARMACEUTICAL COMPOSITIONS
FOR PREVENTION OF
NEOVASCULARIZATION AND FOR
TREATING MALIGNANCIES

1c806 U.S. PTO
09/742993
12/20/00

Atty. Docket No.: CGD-002.0 US

Asst. Commissioner for Patents
BOX REISSUE
Washington, D.C. 20231

ESTABLISHMENT OF OWNERSHIP PURSUANT TO 37 C.F.R. §3.73(b)
and
CONSENT OF ALL ASSIGNEES TO FILING OF REISSUE APPLICATION

Sir:

By virtue of an assignment executed by the inventors Mark Pines and Arnon Nagler on May 30, 1997 and recorded at **Reel 9286/Frame 0993** transferring all right, title, and interest in the above-referenced U.S. patent jointly to (1) Hadasit Medical Research Services and Development Company Ltd., Kiryat Hadassah, 91120 Jerusalem, Israel and (2) Agricultural Research Organization, Ministry of Agriculture, The Volcani Center, 50250 Bet Dagan, Israel, the undersigned officers of the respective Assignees, pursuant to 37 C.F.R. §3.73(b), hereby affirm their joint ownership of U.S. Pat. No. 6,028,075. A copy of the executed assignment and Notice of Recordation is enclosed.

All assignees hereby consent to the filing of a reissue application pursuant to 35 U.S.C. §251.

All assignees hereby appoint Leon R. Yankwich (Reg. No. 30,237) and David G. O'Brien (Reg. No. 46,125), of Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, Massachusetts 02139 (USA) as their attorneys to file and prosecute said reissue application.

CONSENT OF ASSIGNEES TO FILE REISSUE APPLICATION

I declare that I am an official of the Assignee company/organization identified below who is authorized to execute this document on its behalf. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon, or any patent to which this declaration is directed.

(1) The Hadasit Medical Research Services and Development Company Ltd., assignee of U.S. Pat. No. 6,028,075, hereby consents to the filing of the present reissue application for the reissue of U.S. Pat. No. 6,028,075.

Hadasit
medical research services
development Ltd.

21/9/2000
date

Name: Dr. Rafi Hofstein

Title: General Manager

For: Hadasit Medical Research Services and Development Company, Ltd.

* * * *

(2) The Agricultural Research Organization, assignee of U.S. Pat. No. 6,028,075, hereby consents to the filing of the present reissue application for the reissue of U.S. Pat. No. 6,028,075.

Hana Gad. HANA GAD
Gad Haneh.
Director of Accounting Division

Name:

9.11.2000
date

Title:

For: 27/7
Agricultural Research Organization

E. Putievsky
DR. ELI PUTIEVSKY
HEAD OF A.R.O.

REISSUE APPLICATION BY THE INVENTOR, OFFER TO SURRENDER PATENT		Docket Number (Optional) CGD-002.0 US						
<p>This is part of the application for a reissue patent based on the original patent identified below.</p> <p>Name of Patentee(s) Mark Pines, Israel Vlodavsky, Arnon Nagler, Hua-Quan Miao</p> <table border="1"><tr><td>Patent Number 6,028,075</td><td>Date Patent Issued Feb. 22, 1998</td></tr></table> <p>Title of Invention Quinazolinone Containing Pharmaceutical Compositions for Prevention of Neovascularization and for Treating Malignancies</p> <p>I am the inventor of the original patent.</p> <p>I offer to surrender the original patent.</p> <p>1. <input checked="" type="checkbox"/> Filed herein is a certificate under 37 CFR 3.73(b).</p> <p>2. <input type="checkbox"/> Ownership of the patent is in the inventor(s), and no assignment of the patent has been made.</p> <p>One of boxes 1 or 2 above must be checked.</p> <p>The written consent of all assignees owning an undivided interest in the original patent is included in this application for reissue.</p> <table border="1"><tr><td>Signature <i>Mark Pines</i></td><td>Date 2/11/00</td></tr></table> <p>Typed or printed name Mark Pines, co-inventor</p> <p>The assignee owning an undivided interest in said original patent is (set forth below) _____, and the assignee consents to the accompanying application for reissue.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application, any patent issued thereon, or any patent to which this declaration is directed.</p> <p>Name of assignee Hadasit Medical Research Services & Development Co. Ltd. and Agricultural Research Organization</p> <table border="1"><tr><td>Signature of person signing for assignee</td><td>Date</td></tr></table> <p>Typed or printed name and title of person signing for assignee (see consent document attached)</p>			Patent Number 6,028,075	Date Patent Issued Feb. 22, 1998	Signature <i>Mark Pines</i>	Date 2/11/00	Signature of person signing for assignee	Date
Patent Number 6,028,075	Date Patent Issued Feb. 22, 1998							
Signature <i>Mark Pines</i>	Date 2/11/00							
Signature of person signing for assignee	Date							

1c806 U.S. PTO
09/742993
12/20/00

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REISSUE APPLICATION BY THE INVENTOR, OFFER TO SURRENDER PATENT		Docket Number (Optional) CGD-002.0 US
This is part of the application for a reissue patent based on the original patent identified below.		
Name of Patentee(s) Mark Pines, Israel Vlodavsky, Arnon Nagler, Hua-Quan Miao		
Patent Number 6,028,075	Date Patent Issued Feb. 22, 1998	
Title of Invention Quinazolinone Containing Pharmaceutical Compositions for Prevention of Neovascularization and for Treating Malignancies		
I am the inventor of the original patent. I offer to surrender the original patent.		
1. <input checked="" type="checkbox"/> Filed herein is a certificate under 37 CFR 3.73(b). 2. <input type="checkbox"/> Ownership of the patent is in the inventor(s), and no assignment of the patent has been made.		
One of boxes 1 or 2 above must be checked.		
The written consent of all assignees owning an undivided interest in the original patent is included in this application for reissue.		
Signature <i>Israel Vlodavsky</i>	Date <i>Oct. 10, 2000</i>	
Typed or printed name Israel Vlodavsky, co-inventor		
The assignee owning an undivided interest in said original patent is (set forth below) _____, and the assignee consents to the accompanying application for reissue.		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application, any patent issued thereon, or any patent to which this declaration is directed.		
Name of assignee Hadasit Medical Research Services & Development Co. Ltd. and Agricultural Research Organization		
Signature of person signing for assignee	Date	
Typed or printed name and title of person signing for assignee (see consent document attached)		

Jc806 U.S. PTO
 09/742993
 12/20/00


Burden Hour Statement: This form is estimated to take 0.1 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

REISSUE APPLICATION BY THE INVENTOR, OFFER TO SURRENDER PATENT		Docket Number (Optional) CGD-002.0 US						
<p>This is part of the application for a reissue patent based on the original patent identified below.</p> <p>Name of Patentee(s) Mark Pines, Israel Vlodavsky, Arnon Nagler, Hua-Quan Miao</p> <table border="1"><tr><td>Patent Number 6,028,075</td><td>Date Patent Issued Feb. 22, 1998</td></tr></table> <p>Title of Invention Quinazolinone Containing Pharmaceutical Compositions for Prevention of Neovascularization and for Treating Malignancies</p> <p>I am the inventor of the original patent.</p> <p>I offer to surrender the original patent.</p> <ol style="list-style-type: none"><input checked="" type="checkbox"/> Filed herein is a certificate under 37 CFR 3.73(b).<input type="checkbox"/> Ownership of the patent is in the inventor(s), and no assignment of the patent has been made. <p>One of boxes 1 or 2 above must be checked.</p> <p>The written consent of all assignees owning an undivided interest in the original patent is included in this application for reissue.</p> <table border="1"><tr><td>Signature <i>Arnon Nagler</i></td><td>Date <i>9-21-2000</i></td></tr></table> <p>Typed or printed name Arnon Nagler, co-inventor</p> <p>The assignee owning an undivided interest in said original patent is (set forth below) and the assignee consents to the accompanying application for reissue.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application, any patent issued thereon, or any patent to which this declaration is directed.</p> <p>Name of assignee Hadasit Medical Research Services & Development Co. Ltd. and Agricultural Research Organization</p> <table border="1"><tr><td>Signature of person signing for assignee</td><td>Date</td></tr></table> <p>Typed or printed name and title of person signing for assignee (see consent document attached)</p>			Patent Number 6,028,075	Date Patent Issued Feb. 22, 1998	Signature <i>Arnon Nagler</i>	Date <i>9-21-2000</i>	Signature of person signing for assignee	Date
Patent Number 6,028,075	Date Patent Issued Feb. 22, 1998							
Signature <i>Arnon Nagler</i>	Date <i>9-21-2000</i>							
Signature of person signing for assignee	Date							

jc806 U.S. PTO
09/742993
12/20/00

ARNON NAGLER, MSc, MD
Bone Marrow Transplant
Hadassah Univ. Hospital
91120 Jerusalem, Israel

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REISSUE APPLICATION BY THE INVENTOR, OFFER TO SURRENDER PATENT		Docket Number (Optional) CGD-002.0 US
<p>This is part of the application for a reissue patent based on the original patent identified below.</p> <p>Name of Patentee(s) Mark Pines, Israel Vlodavsky, Arnon Nagler, Hua-Quan Miao</p> <p>Patent Number 6,028,075 Date Patent Issued Feb. 22, 1998</p> <p>Title of Invention Quinazolinone Containing Pharmaceutical Compositions for Prevention of Neovascularization and for Treating Malignancies</p> <p>I am the inventor of the original patent.</p> <p>I offer to surrender the original patent.</p> <p>1. <input checked="" type="checkbox"/> Filed herein is a certificate under 37 CFR 3.73(b).</p> <p>2. <input type="checkbox"/> Ownership of the patent is in the inventor(s), and no assignment of the patent has been made.</p> <p>One of boxes 1 or 2 above must be checked.</p> <p>The written consent of all assignees owning an undivided interest in the original patent is included in this application for reissue.</p> <p>Signature  Date 10/16/00</p> <p>Typed or printed name Hua-Quan Miao, co-inventor</p> <p>The assignee owning an undivided interest in said original patent is (set forth below) _____, and the assignee consents to the accompanying application for reissue.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application, any patent issued thereon, or any patent to which this declaration is directed.</p> <p>Name of assignee Hadasit Medical Research Services & Development Co. Ltd. and Agricultural Research Organization</p> <p>Signature of person signing for assignee Date</p> <p>Typed or printed name and title of person signing for assignee (see consent document attached)</p>		

jc806 U.S. PTO
09/742993

